Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating safety, tolerability, and efficacy of relatlimab in relapsed or refractory B-cell malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Relatlimab (relatlimab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hematologic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-24